Los Angeles Capital Management’s Seres Therapeutics MCRB Stock Holding History

Los Angeles Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,155	Closed	-$353K	–	1242
2022 Q4	$353K	Sell	3,155 -878	-22%	-$118K	﹤0.01%	988
2022 Q3	$518K	Sell	4,033 -1,238	-23%	-$127K	﹤0.01%	918
2022 Q2	$362K	Buy	5,271 +1,941	+58%	+$167K	﹤0.01%	1089
2022 Q1	$474K	Buy	3,330 +3	+0.1%	+$461	﹤0.01%	1053
2021 Q4	$554K	Sell	3,327 -11	-0.3%	-$1.75K	﹤0.01%	958
2021 Q3	$465K	Buy	+3,338	New	+$653K	﹤0.01%	1076

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Los Angeles Capital Management's MCRB Position: Q1 2023 in Review

Los Angeles Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 3,155 shares — an estimated $353K sold.

Los Angeles Capital Management first reported a position in MCRB in Q3 2021 and held it in 6 quarters. The position peaked at $554K in Q4 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

Los Angeles Capital Management reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
Los Angeles Capital Management sold 3,155 Seres Therapeutics shares in Q1 2023, an estimated $353K.
Los Angeles Capital Management first reported a position in Seres Therapeutics in Q3 2021 and held it in 6 quarters.
Los Angeles Capital Management's Seres Therapeutics position peaked at $554K in Q4 2021.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on Los Angeles Capital Management's 13F filing for Q1 2023, filed 4 May 2023.